University of Colorado Cancer Center investigator, Jennifer Diamond, MD, and colleagues report promising phase I results of alisertib with TAK-228 against solid tumors including triple-negative breast cancer. Two University of Colorado Cancer Center studies were presented this weekend at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting in Philadelphia, PA showing that using the...